Loading...
By Kristin J. Kelley
The oral antifungal ketoconazole (marketed as Nizoral) should not be used as a first-line treatment for any fungal infection because it may pose a risk for adrenal gland problems and potentially fatal liver injury, the FDA notified clinicians late last week.
Additionally, interactions with other drugs — including dofetilide, quinidine, pimozide, and cisapride — could cause heart rhythm problems.
Ketoconazole's label will now note that the tablets:
are no longer indicated for Candida and dermatophyte infections or for skin and nail infections;
should not be used in patients with acute or chronic liver disease; and
should only be used to treat endemic mycoses infections when patients don't respond to or can't tolerate other antifungal therapies.
Comment
LINK(S):
FDA MedWatch safety alert (Free)
Nizoral prescribing information (Free PDF)